» Articles » PMID: 25419748

Hydroxychloroquine-induced Fatal Toxic Epidermal Necrolysis Complicated by Angioinvasive Rhizopus

Overview
Specialty Dermatology
Date 2014 Nov 25
PMID 25419748
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The majority of toxic epidermal necrolysis (TEN) cases are provoked by "high risk" medications (e.g. allopurinol, aromatic anticonvulsants, nevirapine, oxicam non-steroidal anti-inflammatory agents, and sulfonamides). TEN usually occurs 1 to 8 weeks after initial administration of the offending agent, but re-administration can evoke TEN within hours to days. Hydroxychloroquine has rarely been associated with TEN, with one case proving fatal. Herein, we report a case of hydroxychloroquine-induced fatal TEN complicated by angioinvasive Rhizopus. To our knowledge, this is the first case report of angioinvasive Rhizopus in a TEN patient. Initial misidentification of the offending agent causing TEN also serves as an important teaching point worth highlighting.

Citing Articles

Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review.

Marin S, Martin Val A, Peligero M, Rodriguez-Bernuz C, Perez-Ricart A, Vilaro Jaques L Pharmaceuticals (Basel). 2022; 15(5).

PMID: 35631460 PMC: 9144263. DOI: 10.3390/ph15050634.


.

Juurlink D CMAJ. 2020; 192(41):E1242-E1246.

PMID: 33051326 PMC: 7588256. DOI: 10.1503/cmaj.200528-f.


Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?.

Santos I, Grosche V, Bergamini F, Sabino-Silva R, Jardim A Front Microbiol. 2020; 11:1818.

PMID: 32903349 PMC: 7438404. DOI: 10.3389/fmicb.2020.01818.


Current coronavirus (SARS-CoV-2) epidemiological, diagnostic and therapeutic approaches: An updated review until June 2020.

Nabil A, Uto K, Elshemy M, Soliman R, Hassan A, Ebara M EXCLI J. 2020; 19:992-1016.

PMID: 32788913 PMC: 7415934. DOI: 10.17179/excli2020-2554.


Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials.

Chen C, Pan K, Wu B, Li X, Chen Z, Xu Q Eur J Clin Pharmacol. 2020; 77(1):13-24.

PMID: 32780229 PMC: 7417776. DOI: 10.1007/s00228-020-02962-5.